Q-omics provides the consensus-scored RN7SL792P profile across patient tissues and cancer cell-line models. RN7SL792P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RN7SL792P is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, RN7SL792P RNA expression shows 7,893 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, BRCA, and THYM as cancer lineages where RN7SL792P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL792P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL792P survival associations across molecular data types. RN7SL792P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL792P RNA expression–survival associations across cancer types. High RN7SL792P expression shows unfavorable associations in UCS, BRCA, UCEC, THCA and CESC, but favorable associations in HNSC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for RN7SL792P RNA expression.
This table summarizes RN7SL792P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL792P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL792P shows lower tumor expression in BRCA, THCA and ESCA and higher tumor expression in LUSC. The BRCA box plot shows higher RN7SL792P RNA expression in normal versus tumor tissue (log2 FC = −0.110, t-test p = .025).
This table shows molecular features associated with RN7SL792P in patient tissues and cancer cell lines. In patient samples, RN7SL792P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
